Document 0542
 DOCN  M9610542
 TI    Increased proportion of CD8+ tumor responsive T cells after immunization
       with tum- versus tum+ rat glioma.
 DT    9601
 AU    Siesjo P; Visse E; Sjogren HO; Department of Tumor Immunology,
       Wallenberg Laboratory, University; of Lund, Sweden.
 SO    Cell Immunol. 1995 Oct 15;165(2):225-33. Unique Identifier : AIDSLINE
       MED/96021261
 AB    Previously established immunogenic (tum-) clones of an ENU
       (ethyl-N-nitrosourea)-induced rat glioma, N32, were compared to the
       original tumor concerning their capacity to induce T lymphocyte
       responses after in vivo immunization and in vitro restimulation of
       responder spleen cells in mixed lymphocyte tumor culture (MLTC) assays.
       Quite unexpectedly, original N32 (tum+) in vivo primed spleen cells
       proliferated to the same extent in vitro in response to tum+ stimulator
       cells as did tum- in vivo primed spleen cells. However, flow-cytometric
       analysis of parallel cultures showed a greatly increased proportion of
       CD3+CD8+ lymphocytes in the proliferating responder cell population from
       tum- immunized hosts, contrary to a CD3+CD4+ lymphocyte dominance after
       tum+ immunization. Although the original tum+ N32 tumor cells are not
       capable of inducing a clearly demonstrable isograft rejection response,
       they induce a strong T cell response readily detectable in MLTC assays.
       We propose that the increased CD8+ lymphocyte proliferation could be an
       essential feature of the isograft rejection response induced by tum-
       tumor variants. Possible mechanisms of the augmented CD8+ T cell
       response are discussed.
 DE    Animal  Comparative Study  CD8-Positive T-Lymphocytes/*IMMUNOLOGY  Flow
       Cytometry  Glioma/*IMMUNOLOGY  Graft Rejection  Immunization  Lymphocyte
       Transformation  Rats  Rats, Inbred F344  Support, Non-U.S. Gov't
       Transplantation, Isogeneic  Tumor Cells, Cultured  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).